Ghanshyam Shastri, MD
Pulmonary Disease · Murray, KYNPI 1508159310
Payments from drug & device makers
Across 282 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$789
- Boehringer Ingelheim$385
- Actelion Pharmaceuticals US, Inc.$358
- Regeneron Healthcare Solutions, Inc.$280
- Insmed, Inc.$266
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,53792%
- Education$4208%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 85 | $1,162 |
| AstraZeneca | 41 | $789 |
| Boehringer Ingelheim | 19 | $385 |
| Actelion Pharmaceuticals US, Inc. | 16 | $358 |
| Regeneron Healthcare Solutions, Inc. | 19 | $280 |
| Insmed, Inc. | 12 | $266 |
| Grifols USA, LLC | 16 | $221 |
| Electromed, Inc. | 12 | $177 |
| Sanofi | 9 | $161 |
| Genentech USA, Inc. | 4 | $143 |
| Baxter Healthcare | 8 | $135 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Johnson & Johnson(2 entities) | 3 | $95 |
| Amgen | 1 | $93 |
| Pulmonx Corporation | 5 | $88 |
| Portola Pharmaceuticals, LLC | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $66 |
| Mallinckrodt Hospital Products Inc. | 3 | $51 |
| Merck | 3 | $51 |
| Mylan Specialty L.p. | 3 | $49 |
| Philips North America LLC | 2 | $33 |
| Verona Pharma, Inc. | 2 | $29 |
| Body Vision Medical Inc. | 1 | $24 |
| CSL Behring | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| AbbVie | 1 | $15 |
| Ambu Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OFEV$125
How this compares
$4,957 in reported general payments places this provider in the 45th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 215 | $169,851 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $165,159 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 190 | $141,603 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 86 | $58,871 |
| Spiriva RespimatTiotropium Bromide | 51 | $41,000 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $31,261 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 30 | $15,520 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $15,495 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $14,253 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 292 | $7,413 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $6,057 |
| Roflumilast | 62 | $4,215 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $3,562 |
| Ventolin HfaAlbuterol Sulfate | 44 | $3,242 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $1,546 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,162 | $216,607299 claims |
| Grifols USA, LLCProlastin C | $221 | $165,15912 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $789 | $161,913237 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $385 | $115,391167 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Murray
- John McConnellLouisville$3.5M
- Girish NairLexington$852K
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Firas KouraGeorgetown$423K
- Erica GregonisRichmond$390K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Steven KoenigMorehead$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.